• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 14, 2016

View Archived Issues

Despite PATENCY-1 failure, Proteon vows to press on with vonapanitase

Shares of Proteon Therapeutics Inc. hit a wall after the company disclosed that the phase III PATENCY-1 trial of its recombinant human elastase, vonapanitase, missed its primary endpoint of improved primary unassisted patency compared to placebo. Read More

Pharma productivity continues decline, Deloitte report shows

LONDON – The return on investment in pharma R&D continues to slide, with Deloitte LLP's 2016 report projecting returns of 3.7 percent, compared to 10.1 percent in 2010, when the analysis was first conducted. Read More

Gone fishing: Blackfynn's data platform likely lure for partners in neurology

"We're on the precipice of being able to crack open the science [in neurology]," Amanda Christini, president of Blackfynn Inc., told BioWorld Today. Spun out at the start of 2015 from the University of Pennsylvania, the organization consists of an 11-person team of experts in neurology, neuroscience, computer science, medicine and engineering. Read More

India pharma slow to adopt digitization

NEW DELHI – Looking to keep up with global trends, Indian pharma has moved to speed up its push toward more digitization, but it has a long way to go before it catches up with advanced countries, pharma industry analysts say. Read More

Meds non-adherence costs pharma companies about $637B a year

In order for patients to derive benefit from their medications they have to adhere to the prescribed treatment regimen. In an ideal world dispensed medications for chronic conditions are taken by the patient exactly as prescribed. Sadly, doctors' orders are not always followed for a variety of complex reasons including such factors as the emergence of side effects, length of treatment, the frequency of dosing and severity of the disease to name just a few. As a result medication non-adherence is one of the most serious problems in health care and poses a significant financial drain on the health care system.  Read More

Financings

Soligenix Inc., of Princeton, N.J., said it priced an underwritten public offering of 1.67 million shares of its common stock and warrants to purchase up to an aggregate of 2.08 million shares of its common stock at a combined offering price of $3.16. Read More

In the clinic

Arbutus Biopharma Corp., of Vancouver, British Columbia, reported results from the multiple-dose cohort of its ongoing phase II study of RNAi candidate ARB-1467 in chronically infected hepatitis B virus (HBV) patients on stable nucleotide/nucleoside therapy, showing a significant reduction of HBsAg. Read More

Other news to note

Cytomx Therapeutics Inc., of South San Francisco, said Bristol-Myers Squibb Co., of New York, has selected a clinical candidate for its CTLA-4 Probody program under the companies' strategic oncology collaboration established in May 2014, resulting in a $2 million milestone payment to Cytomx. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe